Trial Profile
A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs CWP 291 (Primary) ; Cytarabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 09 Dec 2021 Planned End Date changed from 1 Oct 2020 to 1 Oct 2022.
- 09 Dec 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2022.
- 15 May 2019 Status changed from recruiting to active, no longer recruiting.